Overview

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

Status:
Enrolling by invitation

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Subjects will participate in three weeks of the bionic pancreas in the insulin-only configuration. Each week, subjects will use a different rapid acting insulin analog -- Humalog, Novolog, or BC222 insulin lispro -- in a randomized cross-over order.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

Boston University

Treatments:

Insulin
Insulin Aspart
Insulin glulisine
Insulin Lispro
Insulin, Globin Zinc
Insulin, Short-Acting
Pancreatin
Pancrelipase